FDA Approves Gammagard Liquid ERC to Treat PI, Plans to Discontinue Gammagard SD in December 2027
The U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for individuals 2 years of age and older with primary immunodeficiency (PI).
Flebogamma (IVIG) Effective in Treating Post-Polio Syndrome
Grifols announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of Flebogamma 5% DIF (intravenous immune globulin [IVIG]) to treat patients with post-polio syndrome, which demonstrated a significant improvement in distance walked compared to placebo.
IVIG Effectively Increased Platelet Counts in Maternal Thrombocytopenia
A recent study that sought to evaluate the efficacy of intravenous immune globulin (IVIG) and identify predictors of platelet response in pregnant persons with moderate-to-severe thrombocytopenia, as well as to optimize clinical decisions and resource use, has found that IVIG effectively increases platelet counts.
Diagnosing and Treating Infant Botulism
Since the approval of BabyBIG, the only treatment for this rare but life-threatening disease affecting infants mostly under 6 months, the mortality rate is now less than 15 percent.
Update on Rabies
Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.
Multiple Myeloma Patients Treated with Teclistamab May Benefit from IVIG Supplementation
Results of a recent study show patients with multiple myeloma undergoing teclistamab therapy may benefit from primary intravenous immune globulin supplementation, which appears to reduce the risk of high-grade infection.
Bivigam, Gamunex-C and Panzyga Lots Withdrawn
Specific lots of intravenous immune globulin (IVIG) and subcutaneous IG (SCIG) have been voluntarily withdrawn by the manufacturers due to a higher rate of allergic/hypersensitivity type reactions, some of which were considered medically significant.
Study Shows IVIG Is Associated with Sepsis Mortality
A study published in Frontiers in Immunology has found the administration of intravenous immune globulin (IVIG) is associated with a reduction in sepsis mortality and favorable outcomes in laboratory parameters and the functional status, contributing to the ongoing debate on the efficacy of IVIG for sepsis.
Study Finds Repeat Dosing of IVIG and PLEX Common in GBS, Resulting in Harm to Nonresponders
According to randomized controlled trials, repeat intravenous immune globulin (IVIG) dosing and plasma exchange (PLEX) followed by IVIG (combination therapy) have no additional therapeutic benefit in Guillain-Barré syndrome (GBS) nonresponders. Furthermore, the delineation between GBS and acute onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) can be particularly challenging and carries therapeutic implications. In the retrospective study […]
The Expanding Role of Immune Globulin Treatment in Diseases: Utilization and Growth
New research showing the therapeutic benefit of immune globulin for treating a variety of autoimmune diseases is contributing to market growth of this essential medicine.
